Impact of azilsartan on proteinuria in patients with chronic kidney disease
Not Applicable
Recruiting
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000008597
- Lead Sponsor
- Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
1. Pregnancy 2. History of hypersensitivity to azilsartan or candesartan 3. Myocardial infarction or stroke in the past 6 months 4. Potassium >= 5.5 mEq/L 5. During lactating 6. Liver dysfunction (ALT > 3-times the upper limit of normal) 7. IgA nephropathy starting steroid therapy within 1 year 8. Known bilateral renal artery stenosis 9. Severe nephrotic syndrome (serum alb < 2g/dL) 10. Active cancer 11. Severe infection 12. Judged as inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint is the difference of the percent changes in urinary protein creatinine ratio between two treatment groups
- Secondary Outcome Measures
Name Time Method 1. Changes of blood pressure 2. Changes of urinary protein creatinine ratio 3. eGFR 4. Changes of urinary angiotensinogen, urinary 8-OHdG, serum osteopontin, plasma MCP-1 and serum IL-6 5. Changes of urinary protein creatinine ratio and blood pressure after switching ARB, ACEI or DRI to azilsartan